CanSino to start Phase III trial of COVID-19 vaccine in Saudi


  • World
  • Sunday, 09 Aug 2020

FILE PHOTO: Chinese vaccine maker CanSino Biologics' sign is pictured on its building in Tianjin, China November 20, 2018. REUTERS/Stringer

DUBAI (Reuters) - Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China's CanSino Biologics Inc <6185.HK>, a Saudi health ministry spokesman said on Sunday.

Last month, CanSino's co-founder said the company was in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of the vaccine candidate, Ad5-nCOV. [nL3N2EI032]

The vaccine uses a harmless cold virus known as adenovirus type-5 (Ad5) to carry genetic material from the coronavirus into the body.

Researchers said last month that CanSino's vaccine, co-developed with China's military research unit, appeared to be safe and induced immune responses in most subjects. [nL3N2ER36S]

Saudi Arabia plans to test the vaccine alongside a placebo on 5,000 volunteers and is currently preparing trials in the cities of Riyadh, Dammam and Mecca, Saudi state news agency SPA said on Saturday.

No COVID-19 vaccine has been approved for commercial use.

CanSino's candidate became the first in China to move into human testing in March but other potential vaccines developed by Sinovac Biotech and a unit of China National Pharmaceutical Group (Sinopharm) have already been approved for Phase III trials overseas. [nL3N2F1452]

(Reporting by Nafisa Eltahir; Writing by Yousef Saba; editing by David Evans)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 18
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

80% readers found this article insightful

Across the site